Gyre Therapeutics (GYRE) Non-cash Items (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Non-cash Items data on file, last reported at $16.2 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $16.2 million, changed 0.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.2 million (changed 0.33% YoY), and the FY2025 annual result was $15.9 million, down 91.63% from the prior year.
• Non-cash Items grew to $16.2 million in Q1 2026 per GYRE's latest filing, from $15.9 million in the prior quarter.
• Over five years, Non-cash Items peaked at $444.2 million in Q4 2023 and troughed at $100000.0 in Q1 2024.
• A 5-year average of $44.8 million and a median of $7.6 million in 2023 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2024 and 2025: Non-cash Items sank 98.65% in 2024, then surged 16118.52% in 2025.
• A 5-year view of Non-cash Items shows it stood at $12.7 million in 2022, then jumped by 3406.73% to $444.2 million in 2023, then sank by 57.14% to $190.4 million in 2024, then slumped by 91.63% to $15.9 million in 2025, then gained by 1.41% to $16.2 million in 2026.
• Business Quant data shows GYRE's Non-cash Items at $16.2 million in Q1 2026, $15.9 million in Q4 2025, and $15.8 million in Q3 2025.